From computational molecular design to GMP-certified manufacturing at scale, our integrated platform bridges the gap between discovery and delivery through rigorous science and proprietary technology.
Our proprietary antibody platform leverages advanced computational biology and high-throughput screening to engineer monoclonal antibodies with superior binding affinity, stability, and manufacturability.
Optimized for high-yield, stable expression of complex glycoproteins with titers exceeding 8 g/L in fed-batch culture.
Machine learning models screen 4,200+ candidates in 72 hours, predicting immunogenicity and developability scores.
End-to-end manufacturing processes designed for WHO Prequalification submission, ensuring global market access for vaccines across Africa and emerging markets.
A comprehensive view of our clinical programs including target mechanisms, therapeutic areas, and modalities. Hover over any candidate for full clinical data.
End-to-end capabilities enabling rapid development and scalable manufacturing.
End-to-end fermentation, inactivation, and polysaccharide-protein conjugation for OCV, Hexavalent, PCV13, and Meningococcal vaccines. From seed culture to bulk drug substance.
In vitro transcription, mRNA purification, and lipid nanoparticle encapsulation. Partnership with WHO mRNA Technology Transfer Hub and Afrigen Biologics for continental mRNA capability.
SAHPRA-aligned analytical methods development, stability testing, and quality control. TrackWise Digital QMS with real-time batch release and GAMP-5 validated data integrity.
Leverage our proprietary platforms and continental manufacturing infrastructure to accelerate your biopharmaceutical programs.